Adagene Inc.
Business
Adagene Inc. is a clinical-stage biotechnology company developing novel antibody-based cancer immunotherapies using its proprietary Dynamic Precision Library (DPL) platform. The company leverages computational biology and three antibody technology platforms—NEObody, SAFEbody, and POWERbody—to engineer differentiated therapeutic candidates. Its lead program, ADG126 (muzastotug), a masked anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer in combination with pembrolizumab. Adagene also maintains a pipeline of earlier-stage candidates and has established technology licensing collaborations with global biopharmaceutical partners including Sanofi, Exelixis, Third Arc Bio, and others to generate royalty and milestone revenues.
Summary from 20-F filed 2026-04-01
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $7.67M |
| Net income | $-17.61M |
| Total assets | $78.26M |
| Total liabilities | $26.36M |
| Stockholders' equity | $35.35M |
| Operating cash flow | $-15.66M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Adagene Inc.'s CIK number?
Adagene Inc.'s SEC CIK number is 0001818838 (1818838). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Adagene Inc.'s SEC filings?
All of Adagene Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.